Placebo controlled trial of fusidic acid gel and oxytetracycline for recurrent blepharitis and rosacea

Br J Ophthalmol. 1995 Jan;79(1):42-5. doi: 10.1136/bjo.79.1.42.

Abstract

A prospective, randomised, double blind, partial crossover, placebo controlled trial has been conducted to compare the performance of topical fusidic acid gel (Fucithalmic) and oral oxytetracycline as treatment for symptomatic chronic blepharitis. Treatment success was judged both by a reduction in symptoms and clinical examination before and after therapy. Seventy five per cent of patients with blepharitis and associated rosacea were symptomatically improved by fusidic acid gel and 50% by oxytetracycline, but fewer (35%) appeared to benefit from the combination. Patients with chronic blepharitis of other aetiologies did not respond to fusidic acid gel but 25% did benefit from oxytetracycline and 30% from the combination. Our results demonstrate the need to investigate patients with blepharitis for concomitant rosacea as they respond well to targeted therapy.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Blepharitis / complications
  • Blepharitis / drug therapy*
  • Chronic Disease
  • Double-Blind Method
  • Drug Therapy, Combination / therapeutic use*
  • Female
  • Fusidic Acid / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Oxytetracycline / therapeutic use
  • Prospective Studies
  • Rosacea / complications
  • Rosacea / drug therapy*

Substances

  • Fusidic Acid
  • Oxytetracycline